Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
The filing reports insider activity by Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics (DGX). On 08/13/2025 he had a disposition of 123 shares of Quest Diagnostics common stock executed under code F at a price of $175.91 per share; the filer states this sale was made solely to cover tax withholding on vested restricted stock units. Following the reported transaction, Kuppusamy beneficially owned 8,338 shares directly, plus 358 shares indirectly via a trust and 1,628 shares held in the 401(k) plan, with the 401(k) amount provided by the plan administrator based on current account balances.
Quest Diagnostics (DGX) filed a Form 144 reporting a proposed sale of 1,903 common shares through Fidelity Brokerage Services (900 Salem Street, Smithfield, RI) with an approximate aggregate market value of $342,54008/15/2025. The filing lists total shares outstanding as 111,823,441. The document also discloses a recent sale by Thomas P. Plewman of 5,535 common shares on 08/06/2025 for gross proceeds of $968,625. The record of acquisition shows numerous small purchases and vesting events (ESPP purchases, dividend reinvestments, restricted stock vesting) between 02/01/2021 and 06/28/2024 that underlie the holdings to be sold.
Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), exercised non-qualified stock options and sold shares under a Rule 10b5-1 plan on 08/06/2025. The filing shows an exercise of 3,560 options at an exercise price of $86.63 and subsequent sales of 3,560 shares at $175 and an additional 1,975 shares at $175. Following these transactions the reporting person beneficially owned 19,219 shares and the reported option grant counts are 0. The filing notes the exercise and sales were effected pursuant to a Rule 10b5-1 sales plan, that the option vested in three annual installments beginning Feb 18, 2020, and that the beneficial ownership total includes exempt purchases under the company stock purchase plan since the last Form 4.
Quest Diagnostics Inc. (DGX) has filed a Form 144 indicating an intended sale of 8,269 common shares through Fidelity Brokerage Services.
- Aggregate market value: $1,384,230.60 (based on the market price on the filing date).
- Percentage of shares outstanding: approx. 0.0074 % of the 111,823,441 shares outstanding — an immaterial level.
- Anticipated sale date: 07 / 30 / 2025 on the NYSE.
- Source of shares: options granted on 18 Feb 2019 (3,045 shares) and 18 Feb 2020 (5,224 shares); cash was paid upon exercise.
No shares were sold during the prior three months, and the signer represents no undisclosed adverse information. The filer’s name, relationship to the issuer, and 10b5-1 plan data were not disclosed in the excerpt.